EUVIMEDEUVIMED entdecken
Crossref

Is it time to include p40 as a standard myoepithelial marker of breast? A comparative study of expression of p63 and p40 in benign breast diseases and invasive ductal carcinomas of the breast

Richa Ranjan, Alpana Gupta, Samresh Singh, Aatirah Cheriaparambath, Raj Singh

Clinical Cancer Investigation Journal · 2021 · 10 (2) · 78-83

DOI: 10.51847/j0rdem4kqd893 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Cancer Investigation Journal, 2021. Verfasst von Richa Ranjan und 4 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Ranjan, R., Gupta, A., Singh, S., Cheriaparambath, A., & Singh, R. (2021). Is it time to include p40 as a standard myoepithelial marker of breast? A comparative study of expression of p63 and p40 in benign breast diseases and invasive ductal carcinomas of the breast. Clinical Cancer Investigation Journal, 10(2), 78-83. https://doi.org/10.51847/j0rdem4kqd893

Vancouver

Ranjan R, Gupta A, Singh S, Cheriaparambath A, Singh R. Is it time to include p40 as a standard myoepithelial marker of breast? A comparative study of expression of p63 and p40 in benign breast diseases and invasive ductal carcinomas of the breast. Clinical Cancer Investigation Journal. 2021;10(2):78-83. doi:10.51847/j0rdem4kqd893

BibTeX
@article{Ranjan2021,
  author = {Ranjan, Richa and Gupta, Alpana and Singh, Samresh and Cheriaparambath, Aatirah and Singh, Raj},
  title = {Is it time to include p40 as a standard myoepithelial marker of breast? A comparative study of expression of p63 and p40 in benign breast diseases and invasive ductal carcinomas of the breast},
  journal = {Clinical Cancer Investigation Journal},
  year = {2021},
  volume = {10},
  number = {2},
  pages = {78--83},
  doi = {10.51847/j0rdem4kqd893}
}
Kostenlos starten →